U.S. Meibomian Gland Dysfunction Market Report 2021-2027 : Recent Study Including Regional Analysis, Applications, Growth Factors And Key Players

Global U.S. Meibomian Gland Dysfunction Market: The report provides a valuable source of insightful data for business strategists and competitive analysis of U.S. Meibomian Gland Dysfunction Market. The study covers important knowledge that makes the analysis document a handy resource for managers, analysts, business consultants and different key individuals get ready-to-access and self-analyzed study in conjunction with graphs and tables to assist perceive market trends, drivers and market challenges.It also highlights the restraints and opportunities expected to influence the market’s growth during the said period. The study provides a holistic perspective on the market’s growth throughout the above mentioned forecast period in terms of revenue(in US$ Mn) and Volume (Thousand Units), across different geographies.

Request Here For PDF Brochure

U.S. Meibomian Gland Dysfunction (MGD) Market, By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), By Drug Type (Cyclosporine, AZR MD 001, Omega-3 supplements, NOV03 (Novatears), Antibacterial Eye Drops, Steroids, TP 03, and HY02–Minocycline), and By Route of Administration (Oral and Topical), is expected to be valued at US$ 1,976.6 million in 2020 and is expected to manifest a CAGR of 15.4% over the forecast period of 2020-2030, as mentioned in a new report published by Coherent Market Insights.

Drivers

Focus of the major companies of the market on launch of innovative products so as to treat the meibomian gland dysfunction (MGD) syndrome, which is expected to propel growth of the U.S. meibomian gland dysfunction market over the forecast period.

In November 2017, TearScience, which is a subsidiary of Johnson and Johnson Vision Care Inc., had launched the LipiFlow and LipiScan technologies in a meeting at the American Academy of Ophthalmology. These technologies will be used for treatment of meibomian gland dysfunction, which is one of the cause of dry eye disease.

In July 2018, the Allergen Plc., had launched the Refresh Repair Lubricant Eye Drops, which is an over-the-counter (OTC) artificial tear formulation. This product is developed repairing and protecting the eyes for hazardous effects of dry eye and hence, enhancing the clarity of vision.

In September 2019, OASIS Medical had launched Oasis Tears Omega 3 and Oasis Tears Vision, as a new line of supplementary diets at Vision Expo West in Las Vegas City.

Impact of COVID-19 epidemic

Major companies contributing in the market have a vigorous pipeline of products for treating the dry eyes related to meibomian gland dysfunction. The companies are focused on making changes in enrolment studies clinically related to SARS-CoV-2 that will aid in completion of clinical trials on time. In March 2020, the clinical drug developing company, RegeneRx, had announced that the company’s Korean collaborator in the U.S., GtreeBNT, will develop RGN-259 in order to treat the dry eye disease, and has issued an update on status of the company’s Phase III clinical trial of dry eye.

The team of GtreeBNT had met with the manager of ARISE-3 trials, contract research organization (CRO), for discussing any possible changes in enrolment related to the SARS-CoV-2 virus. The team is also planning to develop the contingency strategy on the basis of future development or any restrictions imposed by the U.S. or the World Health Organization. Hence, there were no serious delays or disturbances in ARISE-3 trial, and in case there is any need for modification in this clinical plan due to pandemic, GreenBNT will immediately notify its stockholders via its website.

Furthermore, rising ophthalmic incidences as a result of COVID-19 epidemic are poised to boost demand for the ophthalmic preparations. In April 2020, the National Centers for Bio-technological Information had published the results of a study which revealed that the coronavirus has become a global epidemic due to its highly contagious severe acute respiratory syndrome. Various reports of irritation and eye redness in COVID-19 patients have been recorded, hinting that conjunctivitis might be an ocular manifestation of SARS-CoV-2 infection.

Browse 9 Market Data Tables and 21 Figures spread through 132 Pages and in-depth TOC on “Meibomian Gland Dysfunction Market”- U.S. Forecast to 2030, By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), By Drug Type (Steroids, Cyclosporine, AZR MD 001, Omega-3 supplements, Antibacterial Eye Drops, TP 03, NOV03 (Novatears), and HY02 – Minocycline), and By Route of Administration (Oral and Topical).

Focus of major market players on adopting inorganic strategies such as partnerships and agreements to increase their market presence and extend their portfolio of products. In December 2019, a pharmaceutical company, Novaliq GmbH had announced the acquisition of a license for development and commercialization of investigational treatment by Bausch Health, with NOVO3 (perfluorohexyloctane), an investigational drug of novel mechanism function for treating dry disease related to meibomian gland dysfunction in the U.S. and Canada.

Key Takeaways of the U.S. Meibomian Gland Dysfunction Market:

Due to vigorous pipeline of products for treating meibomian gland dysfunction, the U.S. meibomian gland dysfunction market is expected to exhibit a CAGR of 15.4% over the forecast period. In December 2019, a bio-tech company, Aldeyra Therapeutics Inc., had revealed promising outcomes from its Phase IIb clinical trials of topical ocular reproxalap in patients suffering from dry eye disease related to meibomian gland dysfunction syndrome. Reproxalap is a therapy that has an action of novel mechanism and no visible side-effects with quick onset of its action.

According to the type of drug: Due to the launch of newer products, the Cyclosporine segment still holds its dominating position in the U.S. meibomian gland dysfunction market in 2020. In August 2018, SunPharma had received approval for its Cequa (cyclosporine ophthalmic solution) with 0.09% from the U.S. FDA. The drug is developed to increase the production of tear in patients suffering from dry eye disease. It is the only cyclosporine product which is approved and incorporates the nano-micellar technology, with better penetration of active molecule into ocular tissues.

According to the administration route: Due to accessibility of eye ointments, over-the-counter eye drops, and artificial tear solutions for treating the dry eye MGD, the topical segment is poised to maintain its dominating position in the U.S. meibomian gland dysfunction market in 2020.

Major companies contributing in the U.S. meibomian gland dysfunction market include Santen Pharmaceutical Co., Ltd., Pfizer, Inc., AbbVie Inc., RegeneRx, and Akorn, Inc., OASIS Medical, Bausch Health Companies Inc., Novartis AG, Sentiss Pharma Pvt. Ltd., I-MED Pharma Inc., and Johnson and Johnson Vision Care Inc.

Major Key Players Include In U.S. Meibomian Gland Dysfunction Market: Pfizer, Inc., AbbVie Inc., Johnson and Johnson Vision Care Inc., Bausch Health Companies Inc., Novartis AG, Santen Pharmaceutical Co., Ltd., I-MED Pharma Inc., OASIS Medical, Sentiss Pharma Pvt. Ltd., RegeneRx, and Akorn, Inc.

Buy instant copy of this research report with Flat US $ 2000 Off@ – https://www.coherentmarketinsights.com/promo/buynow/4186

Main points in U.S. Meibomian Gland Dysfunction Market Report Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 U.S. Meibomian Gland Dysfunction Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: U.S. Meibomian Gland Dysfunction Industry Impact

Chapter 2 Global U.S. Meibomian Gland Dysfunction Competition by Types, Applications, and Top Regions and Countries
2.1 Global U.S. Meibomian Gland Dysfunction (Volume and Value) by Type
2.3 Global U.S. Meibomian Gland Dysfunction (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global U.S. Meibomian Gland Dysfunction Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America U.S. Meibomian Gland Dysfunction Market Analysis
Chapter 6 East Asia U.S. Meibomian Gland Dysfunction Market Analysis
Chapter 7 Europe U.S. Meibomian Gland Dysfunction Market Analysis
Chapter 8 South Asia U.S. Meibomian Gland Dysfunction Market Analysis
Chapter 9 Southeast Asia U.S. Meibomian Gland Dysfunction Market Analysis
Chapter 10 Middle East U.S. Meibomian Gland Dysfunction Market Analysis
Chapter 11 Africa U.S. Meibomian Gland Dysfunction Market Analysis
Chapter 12 Oceania U.S. Meibomian Gland Dysfunction Market Analysis
Chapter 13 South America U.S. Meibomian Gland Dysfunction Market Analysis
Chapter 14 Company Profiles and Key Figures in U.S. Meibomian Gland Dysfunction Business
Chapter 15 Global U.S. Meibomian Gland Dysfunction Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology

Request for a Sample Report

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com